Barclays
GTBP icon

Barclays’s GT Biopharma GTBP Stock Holding History

Barclays’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-58
Closed -$706 – 5523
2026
Q2 		$706 Buy
+58
New +$588 ﹤0.01% 4963
2022
Q2 		– Sell
-4
Closed -$8K – 5121
2022
Q1 		$8K Buy
+4
New +$8.82K ﹤0.01% 4630

Other funds holding GTBP

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return
Allworth Financial
Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return
Main Street Group
Main Street Group Glen Allen, Virginia $445M AUM 22.95% 1-Year Est. Return
Newbridge Financial Services Group
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
West Financial Advisors
West Financial Advisors Des Moines, Iowa $665M AUM 10.35% 1-Year Est. Return
Triumph Capital Management
Triumph Capital Management Denver, Colorado $573M AUM 15.32% 1-Year Est. Return
Reyes Financial Architecture
Reyes Financial Architecture San Diego, California $162M AUM 20.04% 1-Year Est. Return

Barclays's GTBP Position: Q3 2026 in Review

Barclays sold out of GT Biopharma (GTBP) in Q3 2026, closing a stake of 58 shares — an estimated $706 sold.

Barclays first reported a position in GTBP in Q1 2022 and held it in 2 quarters. The position peaked at $8K in Q1 2022. 10 funds tracked by Wall St. Rank hold GTBP as of Q3 2026.

  • Barclays reported no remaining GT Biopharma position as of Q3 2026 after selling out during the quarter.
  • Barclays sold 58 GT Biopharma shares in Q3 2026, an estimated $706.
  • Barclays first reported a position in GT Biopharma in Q1 2022 and held it in 2 quarters.
  • Barclays's GT Biopharma position peaked at $8K in Q1 2022.
  • 10 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.